{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:24Z","timestamp":1792265064979,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.canrad.2021.01.007","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T07:32:33Z","timestamp":1617694353000},"page":"432-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases"],"prefix":"10.1016","volume":"25","author":[{"given":"C.","family":"Cabanie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Biau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Durando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mansard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Verrelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lapeyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dupic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2021.01.007_bib0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.canrad.2014.11.001","article-title":"Epidemiology of brain metastases","volume":"19","author":"Taillibert","year":"2015","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2021.01.007_bib0210","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomised controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2021.01.007_bib0215","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0220","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-007-0110-8","article-title":"Radiosurgery in the treatment of brain metastases: critical review regarding complications","volume":"31","author":"Maldaun","year":"2008","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.canrad.2021.01.007_bib0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2013.05.015","article-title":"Challenges with the diagnosis and treatment of cerebral radiation necrosis","volume":"87","author":"Chao","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.01.007_bib0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3171\/2014.10.JNS141610","article-title":"Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors","volume":"123","author":"Sneed","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.canrad.2021.01.007_bib0240","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.01.007_bib0245","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0250","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0255","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0260","series-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","author":"Reck","year":"2016"},{"key":"10.1016\/j.canrad.2021.01.007_bib0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.01.007_bib0270","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","article-title":"Radiation-induced cell death mechanisms","volume":"31","author":"Eriksson","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0285","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0290","series-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","author":"Antonia","year":"2017"},{"key":"10.1016\/j.canrad.2021.01.007_bib0295","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canrad.2021.01.007_bib0300","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.adro.2017.07.003","article-title":"Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents","volume":"2","author":"Acharya","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0305","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-018-2795-7","article-title":"The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity","volume":"138","author":"Rahman","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.radonc.2017.08.009","article-title":"Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control","volume":"125","author":"An","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0315","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0320","doi-asserted-by":"crossref","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"6","author":"Skrepnik","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canrad.2021.01.007_bib0325","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0330","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.01.007_bib0335","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multi-fraction (3 \u00d7 9Gy) stereotactic radiosurgery for large (> 2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.01.007_bib0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0345","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0350","doi-asserted-by":"crossref","first-page":"632e4","DOI":"10.1016\/j.wneu.2017.01.101","article-title":"Peri-SRS administration of immune checkpoint therapy for melanoma metastatic to\u00a0the brain: investigating efficacy and the effects of relative treatment timing on lesion response","volume":"100","author":"Yusuf","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.canrad.2021.01.007_bib0355","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","article-title":"Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies","volume":"75","author":"Choong","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2021.01.007_bib0360","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-013-1120-8","article-title":"Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease","volume":"113","author":"Telera","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0365","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-013-1248-6","article-title":"Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS","volume":"115","author":"Stockham","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0370","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0375","doi-asserted-by":"crossref","first-page":"102923","DOI":"10.1016\/j.critrevonc.2020.102923","article-title":"Brain metastasis formation and irradiation by stereotactic radiation therapy combined with immunotherapy: a systematic review","volume":"149","author":"Pin","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2021.01.007_bib0385","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CMR.0000000000000413","article-title":"Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases","volume":"28","author":"Nardin","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.canrad.2021.01.007_bib0390","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.01.007_bib0395","first-page":"402","article-title":"Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primarie","volume":"6","author":"Lanier","year":"2019","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.canrad.2021.01.007_bib0400","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","article-title":"Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity","volume":"7","author":"Minniti","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:33:39Z","timestamp":1761136419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321821000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1278321821000238"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2021.01.007","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2021.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}